As described above, our studies related to PIP-2-mediated therapy for ALI began with the finding that the lung surfactant protein SP-A binds to Prdx6 [27] and inhibits its aiPLA2 activity [28,29]. Here, PRDX6 is linked to acute respiratory distress syndrome.